Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immune response in Stat2 knockout mice.

C Park1, S Li, E Cha

  • 1Department of Microbiology, Columbia University, New York, New York 10021, USA.

Immunity
|February 13, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Retrospective Review of Real-World Patterns of Biologic Use in Dermatology Across Metropolitan, Regional and Rural Settings.

The Australasian journal of dermatology·2026
Same author

Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21).

ESMO open·2025
Same author

Implementation of an automated, real-time mortality prediction tool in trauma patients: Can it do more than just predict mortality?

Injury·2025
Same author

Percutaneous core needle biopsy of 566 peripheral lung lesions: analysis of factors associated with biopsy failure and postprocedural pneumothorax.

Clinical radiology·2025
Same author

Corrigendum to "An open-label, phase IB/II study of abemaciclib with paclitaxel for tumors with CDK4/6 pathway genomic alterations": [ESMO Open 10 (2025) 104106].

ESMO open·2025
Same author

An open-label, phase IB/II study of abemaciclib with paclitaxel for tumors with CDK4/6 pathway genomic alterations.

ESMO open·2025

Stat2 is crucial for type I interferon signaling and immune responses. Its absence in mice leads to increased viral susceptibility and impaired immune regulation, with varied effects across different cell types.

Area of Science:

  • Immunology
  • Molecular Biology
  • Virology

Background:

  • Type I interferons (IFNs) are critical for innate immunity, inducing gene expression via Signal Transducer and Activator of Transcription (STAT) proteins.
  • STAT1 and STAT2 associate to form STAT1 homodimers or the ISGF-3 transcription factor, mediating distinct signaling pathways for different IFNs.
  • STAT1 homodimers signal for IFN-gamma, while ISGF-3 is implicated in type I IFN responses.

Purpose of the Study:

  • To investigate the specific roles of STAT2 and the ISGF-3 complex in type I IFN signaling.
  • To elucidate the consequences of STAT2 deficiency on immune responses and viral susceptibility.

Main Methods:

  • Generation of STAT2-deficient (null) mice through gene targeting.
  • Assessment of immune response defects in STAT2 null mice.

Related Experiment Videos

  • Evaluation of viral infection susceptibility in STAT2 null mice.
  • Comparative analysis of type I IFN response in STAT2-deficient fibroblasts and macrophages.

    • Main Results:

    • STAT2 null mice displayed significant defects in immune response, including heightened susceptibility to viral infections.
    • The autocrine/paracrine loop regulated by type I IFNs was abolished in the absence of STAT2.
    • STAT2-deficient fibroblasts showed a more pronounced defect in responding to type I IFNs compared to macrophages, indicating tissue-specific differences.

    Conclusions:

    • STAT2 is essential for effective type I IFN-mediated gene expression and antiviral immunity.
    • STAT2 deficiency disrupts critical IFN signaling loops, leading to compromised immune function.
    • Tissue-specific variations in STAT2 function highlight the complexity of IFN signaling pathways across different cell types.